Sponsor study identifier
Secondary identifiers
interventional
35
7 countries
15
Study Start
December 1999
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2001
Actual (reported)Study Completion
Not reported
Date not reportedRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Hydration with a saline solution may protect kidney cells from the side effects of chemotherapy. PURPOSE: Randomized phase II trial to compare the effectiveness of glufosfamide with or without hydration in treating patients who have pancreatic cancer that is metastatic or cannot be removed by surgery.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 1999
Date type not reportedThis date has not been verified as actual or estimated.
April 6, 2000
Actual (reported)March 2001
Actual (reported)May 3, 2004
Actual (reported)Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Herlev Hospital - University Hospital of Copenhagen
Herlev, DK-2730, Denmark
Centre Leon Berard
Lyon, 69373, France
CHU de la Timone
Marseille, 13385, France
Centre Eugene Marquis
Rennes, 35064, France
Centre Henri Becquerel
Rouen, 76038, France
Universitats-Krankenhaus Eppendorf
Hamburg, D-20246, Germany
Medizinische Hochschule Hannover
Hanover, D-30625, Germany
Briasoulis E, Pavlidis N, Terret C, Bauer J, Fiedler W, Schoffski P, Raoul JL, Hess D, Selvais R, Lacombe D, Bachmann P, Fumoleau P. Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group. Eur J Cancer. 2003 Nov;39(16):2334-40. doi: 10.1016/s0959-8049(03)00629-4.
Nicholas A. Pavlidis, MD
University of Ioannina
35 participants (actual enrollment reported by the registry).
First Submitted
April 6, 2000
First Posted
May 3, 2004
Study Start
December 1999
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Haemato-Onkologische Praxis und Tagesklinik
Munich, D-80639, Germany
Klinikum Nurnberg
Nuremberg, D-90419, Germany
University of Ioannina
Ioannina, GR-45110, Greece
Rambam Medical Center
Haifa, 31096, Israel
Academisch Ziekenhuis der Vrije Universiteit
Amsterdam, 1117 MB, Netherlands
Inselspital, Bern
Bern, CH-3010, Switzerland
Centre Hospitalier Universitaire Vaudois
Lausanne, CH-1011, Switzerland
Kantonsspital - Saint Gallen
Sankt Gallen, CH-9007, Switzerland
Primary Completion
March 2001
Actual (reported)Last Updated
September 24, 2012
Record last verified: 2012-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: